GlycoNex

GlycoNex FCF per Share

The Free Cash Flow per Share of GlycoNex (4168.TWO) as of Nov 4, 2026 is -1.59 TWD. In the previous year, Free Cash Flow per Share was -2.37 TWD — a change of -32.80% (higher).

FCF per Share

-1.59TWD

YoY

-32.80%

Last updated:

Free Cash Flow per Share of GlycoNex is 2025 -1.59 TWD. Free Cash Flow per Share of GlycoNex was 2024 -2.37 TWD. It decreases by -32.80% higher compared to the previous year.

The GlycoNex FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-1.69 TWD
Jan 1, 2019
-1.67 TWD
Jan 1, 2020
-1.52 TWD
Jan 1, 2021
-1.52 TWD
Jan 1, 2022
-1.65 TWD
Jan 1, 2023
-1.91 TWD
Jan 1, 2024
-2.37 TWD
Jan 1, 2025
-1.59 TWD
The GlycoNex FCF per Share history
YEARFCF per ShareYoY
-1.59TWD-32.80%
-2.37TWD+23.86%
-1.91TWD+16.08%
-1.65TWD+8.11%
-1.52TWD+0.15%
-1.52TWD-8.74%
-1.67TWD-1.35%
-1.69TWD+5.38%
-1.60TWD-50.06%
-3.21TWD-67.48%
-9.87TWD+554.47%
-1.51TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GlycoNex Stock analysis

What does GlycoNex do? GlycoNex, Inc. develops anti-cancer monoclonal antibodies and bio-similar drugs, offering licensing for monoclonal antibody targets and carbohydrate antigen and protein drug services. The company targets domestic and Asian markets, distributing its products through these regions. Revenue comes from drug development, licensing agreements, and service provision for antibody targets and related biotech solutions. GlycoNex focuses on anti-cancer monoclonal antibody new drugs and bio-similar drugs, with services including carbohydrate antigen and protein drug related offerings. The firm serves domestic and overseas markets in Asia, generating income from product development, licensing, and specialized biotech services. Its business model relies on developing and commercializing innovative cancer treatments and related services in key Asian markets. The company's revenue streams include the development of anti-cancer monoclonal antibody new drugs, bio-similar drugs, and the licensing of monoclonal antibody targets. Services related to carbohydrate antigen and protein drug solutions are also part of the business, distributed across domestic and Asian markets to generate income from pharmaceutical innovation and biotech service contracts. GlycoNex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GlycoNex stock

Free Cash Flow per Share of GlycoNex is -1.59 TWD in 2025.

Free Cash Flow per Share of GlycoNex changed from -2.37 TWD to -1.59 TWD, representing a -32.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share GlycoNex since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — GlycoNex

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — GlycoNex